Eisai hit with Cancer Drugs Fund 'double Whammy'
This article was originally published in Scrip
Eisai has managed to ensure patients in England get access to its end-of-life breast cancer drug Halaven (eribulin), but at a big cost to the company that will have a "direct impact on its activity in the UK". The firm also complained it had been hit with a "double whammy" from the Cancer Drugs Fund after it said it wouldn't be assessing Lenvima (lenvatinib) for thyroid cancer.
You may also be interested in...
Eisai Predicts "Mayhem" For Kisplyx After NICE Finally Okays Halaven
On the basis of its experience with Halaven, Eisai is predicting that its kidney cancer drug Kisplyx will face a difficult journey getting the OK from NICE, England's health technology appraisal institute.
Novo Nordisk Hit With UK Industry Association Suspension Over Weight Loss Drug Promotion
Novo Nordisk has been hit by a serious sanction in the UK after having been found to effectively pay pharmacists to promote Saxenda.
UK ABPI Suspends Novo Nordisk Over Code Breach
Novo Nordisk has been given a two-year suspension from membership of the Association of the British Pharmaceutical Industry for breaching the association’s code of practice.